Methods for treating conditions associated with MASP-2 dependent complement activation

A technology of MASP-2 and complement activation, which is applied in chemical instruments and methods, biochemical equipment and methods, and resistance to vector-borne diseases, etc. It can solve the complexity and diversity of carbohydrate structures and it is difficult to determine the shared molecular determinants And other issues

Inactive Publication Date: 2007-08-15
OMEROS CORP +1
View PDF39 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The only feature shared by these activators is the presence of carbohydrates, but the complexity and diversity of carbohydrate structures make it difficult to identify shared molecular determinants, which are well recognized

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating conditions associated with MASP-2 dependent complement activation
  • Methods for treating conditions associated with MASP-2 dependent complement activation
  • Methods for treating conditions associated with MASP-2 dependent complement activation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0436] This example describes the generation of a mouse strain deficient in MASP-2 (MASP-2- / -) but sufficient in MAp19 (MAp19+ / +).

[0437] Materials and methods: The targeting vector pKO-NTKV 1901 was designed to disrupt the three exons encoding the C-terminus of murine MASP-2, including the exon encoding the serine protease domain, as shown in Figure 4. PKO-NTKV 1901 was used to transfect the murine ES cell line E14.1a (SV129Ola). Neomycin resistant and thymidine kinase sensitive clones were selected. 600 ES clones were screened, among which four different clones were identified, which were confirmed by southern blotting to contain the expected selective targeting and recombination results, as shown in FIG. 4 . Chimeras were generated from these four positive clones by embryo transfer. The chimeras were then backcrossed in the genetic background C57 / BL6 to generate transgenic males. Transgenic males were crossed with females to produce F1, and 50% of the offspring showed...

Embodiment 2

[0441] This example demonstrates that MASP-2 is required for complement activation via the alternative and lectin pathways.

[0442] Methods and materials:

[0443] Lectin pathway-specific C4 cleavage assays: The C4 cleavage assay has been described by Petersen, et al., J. Immunol. Methods 257:107 (2001), which measures the production of L-ficolin-bound lipoteichoic acid (LTA) from Staphylococcus aureus. Lectin pathway activation. The assay described in Example 11 was modified to measure lectin pathway activation by MBL by coating plates with LPS and mannan or zymosan, followed by addition of serum from MASP-2- / - mice, as described below. The assay was also modified to eliminate the possibility of C4 cleavage due to the classical pathway. This can be achieved by using a sample dilution buffer containing 1M NaCl, which allows high-affinity binding of the lectin pathway recognition components to their ligands, but prevents activation of endogenous C4, thereby dissociating...

Embodiment 3

[0470] This example describes the generation of a transgenic mouse line that is murine MASP-2- / -, MAp19+ / +, and expresses a human MASP-2 transgene (mouse MASP-2 knockout, human MASP-2 knockin).

[0471] Materials and methods: A miniature gene (SEQ ID NO: 49) encoding human MASP-2 called "miniature hMASP-2" shown in Figure 5 was constructed, which included the promoter region of the human MASP 2 gene, including the first 3 exons ( Exon 1 to Exon 3) is followed by a cDNA sequence representing the coding sequence for the next 8 exons, encoding the full-length MASP-2 protein driven by its endogenous promoter. The miniature hMASP-2 construct was inserted into MASP-2- / - zygotes to transgenically express human MASP-2 in place of the missing murine MASP 2 gene.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C l q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.

Description

field of invention [0001] The present invention relates to methods of inhibiting the adverse effects of MASP-2 dependent complement activation. Background of the invention [0002] The complement system provides an early mechanism of action to initiate and enhance the inflammatory response to microbial infection and other acute insults (Liszewski, M.K. and J.P. Atkinson, 1993, in Fundamental Immunology, 3rd edition, edited by W.E. Paul, Raven Press, Ltd. , New York). Although complement activation provides an important first line of defense against potential pathogens, complement activity that promotes a protective inflammatory response may also represent a potential threat to the host (Kalli, K.R., et al., Springer Semin. Immunopathol. 15 : 417-431, 1994; Morgan, B.P., Eur. J. Clinical Investig. 24: 219-228, 1994). For example, C3 and C5 protein hydrolysates recruit and activate neutrophils. These activated cells release destructive enzymes indiscriminately, potentially ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P9/00A61P21/00A61P37/00A61K31/00A61K38/02C07K16/40
CPCC07K16/40C07K2317/24C12N9/6424C07K2317/55A01K67/0276A01K2217/075C07K2317/76A01K2227/105A01K2267/03A61K2039/505C07K16/18A61P9/00
Inventor H·-W·施韦布勒C·M·斯托弗C·E·特德福特J·B·帕伦特T·福吉塔
Owner OMEROS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap